Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
B. Hutyrova (Olomouc, Czech Republic). Effect of omalizumab treatment on allergic comorbidities in patients with severe allergic asthma – real life experience from Czech Anti-IgE Registry. 3541

Member's Comments

No comment yet.

Related content which might interest you: Effectiveness of omalizumab in improving quality of life in patients with ‘steroid-resistant‘ asthma and severe allergic rhinitis Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012 Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017 Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 The ’real-life’ long-term efficacy of omalizumab in severe persistent IgE-mediated allergic asthma in Malta Source: International Congress 2016 – Asthma management Year: 2016 One year following a real life experience of omalizumab for moderate to severe persistent allergic asthma in Malta Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey Source: Eur Respir J 2013; 42: 1224-1233 Year: 2013 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Real-life long-term omalizumab therapy in children with severe allergic asthma Source: Eur Respir J 2015; 46: 856-859 Year: 2015 Treatment and outcomes in patients with asthma and allergic rhinitis Source: Eur Respir J 2005; 26: Suppl. 49, 576s Year: 2005 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Improvements in asthma control and quality of life with omalizumab in allergic (IgE-mediated) asthma patients Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 Asthma control with omalizumab treatment in severe allergic asthma and severe non-allergic asthma patients Source: International Congress 2015 – Asthma and lung immunology Year: 2015 BTS Difficult Asthma Registry: Effect of omalizumab dosing table expansion on size of population of severe persistent allergic asthma patients potentially eligible for omalizumab therapy Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 Safety of omalizumab therapy in children with allergic asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Asthma control and exacerbation rate with omalizumab in Italian patients with severe allergic asthma: PROXIMA study Source: International Congress 2017 – Asthma management Year: 2017 ‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study Source: Annual Congress 2011 - Asthma management and response Year: 2011 Efficacy of Omalizumab in adult and pediatric severe allergic asthma according to presence of multiple allergic comorbidities: evidence from the STELLAIR study. Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab. Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018